Pulse Biosciences filings document regulatory disclosures for a Delaware medical technology company developing nPulse nanosecond pulsed field ablation technology. Its 8-K reports cover clinical and Regulation FD disclosures for the nPulse Cardiac Catheter System, atrial fibrillation study updates, investor presentation materials, and development priorities in electrophysiology, cardiac surgery, and soft tissue ablation.
The company's SEC record also includes proxy materials on board governance, executive compensation, equity awards, and shareholder voting matters. Other filings address capital structure, common stock financing arrangements, officer appointments, compensatory arrangements, operating and financial results, ownership matters, and risk factors tied to its technology development and clinical regulatory activities.
Pulse Biosciences is a pre-commercial medical device company developing Nano-pulse Stimulation (nsPFA) ablation technology across cardiology and soft tissue applications. It has FDA 510(k) clearance for its Vybrance Percutaneous Electrode System for soft tissue ablation and has completed more than 300 patient procedures.
The company is advancing a cardiac surgical clamp and endocardial catheter for atrial fibrillation, supported by Breakthrough Device Designation and approved Investigational Device Exemptions for pivotal studies in the United States and Europe. Pulse holds over 250 issued patents but has no significant revenue, continues to incur losses, and warns that additional capital and favorable reimbursement are critical to its plans.
PULSE BIOSCIENCES, INC. Chief Commercial Officer Kevin Patrick Danahy exercised stock options and sold shares in mid-February. He exercised options covering 60,000 shares of Common Stock at a strike price of $1.53 per share and sold 60,000 shares in open-market transactions at weighted average prices of $23.37, $23.53, and $23.63 per share.
These trades were executed under a Rule 10b5-1 trading plan adopted on May 14, 2025. Following the transactions, Danahy directly holds 43,298 shares of Common Stock and 305,000 stock options from a 2022 grant for up to 450,000 shares that vests over four years.
A shareholder of PLSE has filed a Form 144 notice indicating an intention to sell 50,000 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $1,262,500. The shares relate to an exercise of stock options for 50,000 common shares paid in cash on 02/12/2026.
The filing notes that 67,767,578 shares of the issuer’s common stock were outstanding and that the planned sale is expected around 02/12/2026 on the NASDAQ. It also discloses prior Rule 10b5-1 sales for Kevin Danahy over the past three months, including 20,000-share transactions on 02/09/2026, 02/10/2026, and 02/11/2026 with stated gross proceeds of $429,070.00, $470,498.00, and $503,924.00.
Pulse Biosciences Chief Commercial Officer Kevin Patrick Danahy reported a series of option exercises and share sales in Pulse Biosciences, Inc. common stock. On February 9, 10, and 11, 2026, he exercised 20,000 stock options at an exercise price of $1.53 per share each day, converting them into 20,000 common shares per day.
On each of those same dates, he then sold 20,000 common shares in open-market transactions at weighted average prices of $21.45, $23.52, and $25.20 per share, respectively, leaving 43,298 common shares held directly after each day’s sale. These trades were carried out under a Rule 10b5‑1 trading plan adopted on May 14, 2025.
Following the reported transactions, Danahy directly holds 365,000 stock options with an exercise price of $1.53 per share, originally granted on September 23, 2022 for up to 450,000 shares, with 25% vesting on each anniversary of the grant date.
A shareholder of Pulse Biosciences (PLSE) has filed a notice to sell 75,000 shares of common stock under Rule 144. The shares are to be sold through Morgan Stanley Smith Barney LLC on the NASDAQ, with an aggregate market value of $1,556,250 based on the filer’s stated price.
The securities were acquired on 02/09/2026 through a cash exercise of stock options from the issuer, with payment also made on that date. The form indicates no other sales of the issuer’s securities by this person in the past three months.
Pulse Biosciences director Maria Sainz received new stock options in early 2026. On January 8, 2026, she was granted options to buy 50,000 shares of common stock at $14.72 per share. On February 5, 2026, she received options for 3,104 shares at $13.69 per share.
One-third of the 50,000-share grant will vest on the one-year anniversary of the grant, with the rest vesting monthly over the following two years, assuming continued service. The 3,104-share grant will vest in equal installments on March 5, 2026 and June 5, 2026, also conditioned on continued service.
Pulse Biosciences, Inc. director reports no share ownership
Maria Sainz, a director of Pulse Biosciences, Inc., filed an initial Form 3 reflecting her position with the company as of 01/08/2026. The filing states that no non-derivative or derivative securities of Pulse Biosciences are beneficially owned.
Pulse Biosciences, Inc. reported new 6- and 12‑month results from its first‑in‑human feasibility study of the nPulse Cardiac Catheter System for treating atrial fibrillation. In an initial cohort of 150 patients, procedural success was 100% in 75 evaluable patients at 6 months and 96% in 47 evaluable patients at 12 months.
Across 150 treated patients, serious adverse events related to the primary safety endpoint occurred in 1.3% of subjects (2/150). Procedures used an average of 16.1 ± 5.2 applications, with total procedure and fluoroscopy times of 65 ± 28 and 9.8 ± 5.8 minutes, and left atrial dwell time of 21.0 ± 13.3 minutes.
Pulse Biosciences, Inc. furnished a current report describing that on January 14, 2026 it posted an updated investor presentation on its website. The updated deck highlights recent progress in product development programs for its proprietary nPulse Vybrance Percutaneous Electrode, nPulse Cardiac Clamp and nPulse Cardiac Catheter. The company plans to use this presentation in meetings with investors, analysts and others, and has attached it as Exhibit 99.1 and made it available in the Investors section of its website. The information is provided under a Regulation FD disclosure item and is treated as “furnished,” not “filed,” which limits certain legal liabilities.
Pulse Biosciences, Inc. reported that its Board of Directors elected Maria Sainz as a director, effective immediately, and appointed her to the Audit Committee. She will serve until the 2026 annual meeting of stockholders, subject to earlier departure events. Sainz is currently President and Chief Executive Officer of Hyperfine, Inc. and brings over 30 years of healthtech operating experience, including prior CEO roles at AEGEA Medical, CardioKinetix, and Concentric Medical, and board roles at several listed medical technology companies.
Under the company’s non-employee director compensation policy, Sainz is entitled to an annual cash retainer of $55,000 for Board service and $13,000 for Audit Committee service, paid quarterly, with the option to convert some or all of these retainers into stock options. She received an initial option to purchase 50,000 shares of common stock, vesting over three years, and will be eligible for annual options to purchase 30,000 shares at each future annual meeting, vesting over one year, while she remains a director. The company also noted there are no family relationships or related party transactions involving Sainz and disclosed a press release announcing her appointment.